Epion Therapeutics has been granted a new U.S. patent for its novel light therapy device, a core component of the EpiSmart Epithelium-On Cross-linking System.
This patent further bolsters Epion’s extensive intellectual property portfolio, which includes robust protection in Europe. The EpiSmart System is protected by 12 US and 3 European patents.
Currently in phase 3 clinical trials across the United States, EpiSmart is designed to offer safer, less invasive keratoconus treatment with rapid recovery and simultaneous treatment of both eyes.
This patent marks a significant step in protecting Epion’s technology and supporting the company’s commitment to advancing ophthalmic care.
About Epion Therapeutics
Epion is developing EpiSmart, a minimally-invasive treatment for keratoconus and ectatic corneal disease that could bring early intervention to millions of patients globally. Our approach is a transformative cross-linking system designed to treat keratoconus without chemical or mechanical disruption of the epithelium, allowing for a rapid return to normal activities.